Loss of CD166 does not block prostate tumor progression and tumor initiating cell function in <i>Pb-Cre⁺;Pten^L/L;CD166</i>^−/− mice.

<p>(A) Evaluation of <i>CD166</i> deletion on prostate cancer progression (HE staining, scale bar: 200 µm), cell proliferation (Ki67 staining, scale bar: 100 µm), and prostate tumor invasion (SMA staining, scale bar: 100 µm) by comparing age matched <i>Pb-Cre⁺, Pten^L/L, CD166^+/+</i> and <i>Pb-Cre⁺, Pten^L/L, CD166</i>^−/− prostate tissue at 20 weeks of age. (B) Comparison of sphere formation from total unsorted prostate cells (5000 per 12-well) between <i>Pb-Cre⁺, Pten^L/L, CD166^+/−</i> and <i>Pb-Cre⁺, Pten^L/L, CD166^−/−</i> prostate (9 weeks of age). (C) A representative FACS blot shows LSC content between <i>Pb-Cre+, Pten^L/L, CD166^+/−</i> and <i>Pb-Cre⁺, Pten^L/L, CD166^−/−</i>. (D) Examination of protein levels of CD166, P-AKT and GFP among different prostate tissue with indicated genotype by Western blotting. GADPH is included as an equal loading control.